Foundation Medicine said this week that it is working with Array BioPharma to help identify cancer patients who will respond to targeted therapy with Array's cancer agents.
Under the collaboration, Foundation Medicine will use its DNA sequencing and analysis capabilities to determine the genetic profile of tumors from patients who are treated with Array's drugs.
Array BioPharma has a number of targeted cancer agents in early stages of clinical development. The goal of the partnership is to be able to identify patients who may respond to treatment with a specific drug.
Foundation Medicine already has a number of other partnerships with pharmaceutical companies, including Sanofi, Johnson & Johnson, Novartis, and Celgene.
The company plans to launch its targeted sequencing-based cancer diagnostic test to identify clinically actionable mutations in June (CSN 2/22/2012).